Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A definitive diagnosis of Type 1 Primary Hyperoxaluria (PHI) as confirmed by hepatic angiotensinogen (AGT) deficiency, biochemical criteria (marked hyperoxaluria and hyperglycolic aciduria) or mutation analysis (having a known PHI mutation)~2. Alanine-glyoxylate aminotransferase (AGXT) genotype known~3. Hyperoxaluria not fully corrected by 3 months of continuous Vitamin B6 (VB6) at doses of 8 mg/kg/d or more~4. Males or females, 6-70 years of age, inclusive~5. Preserved renal function, as defined by measured glomerular filtration rate (GFR) \> 30 ml/min/1.73 m\^2~6. Sexually active female patients of childbearing potential must practice adequate contraception during the treatment period and for 6 months after discontinuation of therapy. A pregnancy test obtained at entry prior to the initiation of treatment must be negative. Female patients must not be breast-feeding. Sexually active male patients must practice acceptable methods of contraception during the treatment period and for 6 months after discontinuation of therapy.~7. Written informed consent for participation in this study.~Exclusion Criteria:~1. Patients who are fully VB6 responsive (i.e., G170R homozygotes).~2. Prior recipients of liver transplantation performed for correction of AGT deficiency.~3. Pregnancy or breastfeeding~4. Unwillingness of patient and/or partner to use contraception during treatment.~5. Malignant disease (other than non-melanoma skin cancer) in the previous two years.~6. Markedly reduced renal function (Stage IV Chronic Kidney Disease or measured or estimated GFR \< 30 ml/min/1.73 m\^2)~7. Allergy to betaine or related compounds~8. History of papilledema or increased intracranial pressure.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Betaine (Type: EXPERIMENTAL): Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses. This was followed by a 2 month washout period. Subjects then received the alternative study medication, oral lactose placebo, in two doses daily, for 2 months.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects were randomly assigned to receive oral lactose placebo, in two doses daily, for 2 months. This was followed by a 2 month washout period. Subjects then received the alternative study medication, oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).